MCRB - セレス・セラピュ―ティックス （Seres Therapeutics Inc.） セレス・セラピュ―ティックスMCRBのチャート
MCRBの企業情報
| symbol | MCRB |
|---|---|
| 会社名 | Seres Therapeutics Inc （セレス・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 セレス・セラピューティクス(Seres Therapeutics Inc.)はマイクロバイオーム治療プラットフォーム会社である。同社はエコビオティック微生物治療薬という生物薬の開発に従事する。同社の医薬品は、ジビオティック微生物の機能を修復することによって健康を回復するように設計される。同社は、結腸微生物の不全症を治療するエコビオティック・マイクロビオム治療法を開発するために、その微生物治療プラットフォームを実施する。SER-109はクロストリジウム・ディフィシル感染症（CDI）のさらなる再発を防ぐために設計されたリード製品候補である。同社は、主要なCDIの初期再発を防ぐためのSER-262、潰瘍性大腸炎を含む炎症性腸疾患（IBD）を治療するためのSER-287およびSER-301、並びに腸内細菌病原体を治療するためのSER-155を含む他の製品候補を開発する。 セレス・セラピュ―ティックスは米国のマイクロバイオ―ム治療法プラットフォ―ム開発企業。生物学的薬剤を開発し、腸内の微生物群であるマイクロバイオ―ムの機能を元に戻す治療法に取り組む。クロストリジウム・ディフィシル感染症の再発を防ぐSER-109、潰瘍性大腸炎を治療するSER-287、抗生物質抵抗性バクテリアを処理するSER-155を開発する。 Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. |
| 本社所在地 | 200 Sidney Street - 4th Floor Cambridge MA 02139 USA |
| 代表者氏名 | Roger Pomerantz ロジャー・ポメラント |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 617-945-9626 |
| 設立年月日 | 40452 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 138人 |
| url | www.serestherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mcrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -85.82700 |
| 終値（lastsale） | 6.77 |
| 時価総額（marketcap） | 276186638.51 |
| 時価総額 | 時価総額（百万ドル） 266.39570 |
| 売上高 | 売上高（百万ドル） 34.65400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 170.32970 |
| 当期純利益 | 当期純利益（百万ドル） -91.59400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Seres Therapeutics Inc revenues increased 42% to $8.6M. Net loss increased 4% to $55.7M. Revenues reflect Collaboration revenue - related party increase of 33% to $8M. Higher net loss reflects Research and development expenses increase of 10% to $43.3M (expense) Interest income decrease of 75% to $349K (income) General and administrative expenses increase of 6% to $13.1M (expense). |
MCRBのテクニカル分析
MCRBのニュース
It would be worthwhile to take a closer look at Seres Therapeutics Inc. (MCRB) 2022/11/29 15:00:00 US Post News
A share of Seres Therapeutics Inc. (NASDAQ:MCRB) closed at $7.05 per share on Monday, down from $7.15 day before. While Seres Therapeutics Inc. has underperformed by -1.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -24.60%, with highs and lows ranging from $11.69 […]
GOOGL, SDGR and MCRB are among after hour movers 2022/11/28 22:39:59 Seeking Alpha
Gainers: Kala Pharmaceuticals (KALA) +19%. Alphabet (GOOGL) +7%
Can you still get a good price for Seres Therapeutics Inc. (MCRB) Shares at this point? 2022/11/24 13:16:00 US Post News
Seres Therapeutics Inc. (NASDAQ:MCRB) marked $7.06 per share on Wednesday, up from a previous closing price of $6.64. While Seres Therapeutics Inc. has overperformed by 6.33%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -26.38%, with highs and lows ranging from $11.69 to […]
These strategies will help Seres Therapeutics Inc. (MCRB) succeed 2022/11/14 16:48:00 US Post News
Seres Therapeutics Inc. (NASDAQ:MCRB) closed Friday at $7.17 per share, down from $7.50 a day earlier. While Seres Therapeutics Inc. has underperformed by -4.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MCRB fell by -5.41%, with highs and lows ranging from $11.69 to $2.50, whereas […]
Seres Therapeutics Inc. (NASDAQ: MCRB)’s -16.57-Percent Loss Of This Past Week Taught Us Something New 2022/11/11 13:30:00 Marketing Sentinel
Seres Therapeutics Inc. (NASDAQ:MCRB)’s traded shares stood at 1.39 million during the last session, with the company’s beta value hitting 2.79. At the close of trading, the stock’s price was $7.50, to imply an increase of 5.34% or $0.38 in intraday trading. The MCRB share’s 52-week high remains $11.69, putting it -55.87% down since that … Seres Therapeutics Inc. (NASDAQ: MCRB)’s -16.57-Percent Loss Of This Past Week Taught Us Something New Read More »
Seres Therapeutics stock slips on $100M stock offering 2022/06/30 11:36:07 Seeking Alpha
Seres Therapeutics (MCRB) shares dropped ~8% pre-market after the microbiome therapeutics company launched a $100M offerinf of common stock.Then offering consists of 31,746,030 shares…
NVAX, SAFM and MCRB among after hour mover 2022/06/21 21:23:41 Seeking Alpha
Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%
MCRB,CKPT and RDBX among pre market gainers. 2022/06/16 12:17:44 Seeking Alpha
Redbox Entertainment (RDBXW) +70%. Sidus Space (SIDU) +45%.Redbox Entertainment (RDBX) +18%. Seres Therapeutics (MCRB) +13%. Checkpoint Therapeutics (CKPT) +12%
Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens 2022/06/09 16:08:19 Seeking Alpha
Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. Read more on MCRB stock here.
79 Biggest Movers From Yesterday 2022/06/08 08:08:00 Benzinga
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC ) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company''s pūrgo technology, classifying it as a class II medical device. Applied UV, Inc. (NASDAQ: AUVI ) gained 96.4% to close at $2.18. Kiromic BioPharma, Inc. (NASDAQ: KRBP ) shares jumped 74.3% to close at $0.5020 on Tuesday after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic''s Gamma Delta T cell allogeneic therapies. JanOne Inc. (NASDAQ: JAN ) shares gained 62.8% to settle at $4.07 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) rose 61.8% to close at $1.15. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share. Oncorus, Inc. (NASDAQ: ONCR ) rose 48.7% to close at $1.65. Energy Focus, Inc. (NASDAQ: EFOI ) gained 46.2% to settle at $2.28.
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call Transcript 2022/05/04 17:12:18 Seeking Alpha
Seres Therapeutics, Inc. (NASDAQ:NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President…
Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M 2022/05/04 11:11:11 Seeking Alpha
Seres Therapeutics press release (MCRB): Q1 GAAP EPS of -$0.61 misses by $0.09.Revenue of $1.49M (-74.0% Y/Y).
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates 2022/05/04 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrent C. difficile infection (rCDI). Given the robust profile of SER-109 observed in our Phase 3 study, we expect the product to have a significant impact on rCDI, a serious disease with approximate
Seres Therapeutics Q1 2022 Earnings Preview (NASDAQ:MCRB) 2022/05/03 15:03:29 Seeking Alpha
Seres Therapeutics (MCRB) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.50 (-28.2% Y/Y) and the consensus…
Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months 2022/04/30 12:30:00 Marketing Sentinel
In last trading session, Seres Therapeutics Inc. (NASDAQ:MCRB) saw 0.62 million shares changing hands with its beta currently measuring 3.40. Company’s recent per share price level of $4.73 trading at -$0.14 or -2.87% at ring of the bell on the day assigns it a market valuation of $465.95M. That closing price of MCRB’s stock is … Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months Read More »